News
Featured News
Elixirgen Scientific Japan Awarded Best CDMO Finalist at Citeline Awards Japan – 2024 by Citeline
September 30, 2024
FUJISAWA (SEPTEMBER 30, 2024) – Elixirgen Scientific Japan, Inc (EsJ), a Japanese provider of synthetic mRNA contract development and manufacturing services, was awarded Best CDMO Finalist at Citeline Award Japan – 2024 by Citeline. Recognized for its excellence in delivering innovative and high-quality solutions in mRNA manufacturing, EsJ has demonstrated significant advancements in this field […]
Featured News
Elixirgen Scientific Launches Proprietary In Vitro Assay Service Designed for Rett Syndrome
September 03, 2024
Ricoh Develops a New Pathological Model for Rett Syndrome in iPSC-derived Neurons Baltimore, MD, USA (August 30, 2024) －Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery through hiPSC technology, announced today the launch of its new in vitro assay service for Rett syndrome that mimics the disease pathology. This cutting-edge assay was [...]
Featured News
Elixirgen Scientific and Mitsubishi Tanabe Pharma America Announce a Cell Supply Agreement for the Manufacturing of Human iPSC-Derived CNS Cell Types
July 24, 2024
Baltimore-based biotechnology leader, Elixirgen Scientific, Inc. signs an agreement with Mitsubishi Tanabe Pharma America, Inc. to supply human iPSC-derived neurons and glial cells, strengthening commitment to innovation and collaboration in drug discovery. Baltimore, MD, & Jersey City, NJ, USA (July 24, 2024) – Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and [...]
Featured News
Elixirgen Scientific Launches Advanced hiPSC-Derived Disease Panel for Alzheimer’s Disease
July 15, 2024
Maryland-based biotechnology leader, Elixirgen Scientific, Inc., launches Alzheimer’s Disease Panel, strengthening their commitment to quality and innovation in disease research and drug discovery. Baltimore, MD, USA (July 12, 2024) – Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through hiPSC technology, announced today the launch of its new [...]
Featured News
Elixirgen Scientific Achieves ISO 9001 Certification, Strengthening Commitment to Excellence in Biotechnology
March 12, 2024
Baltimore, Maryland, USA (March 12, 2024) – Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through iPSC technology, announced today that it has been accredited for ISO 9001:2015 certification. The certification is an internationally recognized standard developed by the International Organization for Standardization (ISO) that ensures a company’s [...]
Featured News
Elixirgen Scientific Japan Awarded Top 10 CDMOs in APAC 2023
December 01, 2023
Fujisawa, Japan (December 07, 2023) – Elixirgen Scientific Japan, Inc (EsJ), a Japanese provider of synthetic mRNA contract development and manufacturing services, was awarded TOP 10 CDMOs in APAC - 2023 by Pharma Tech Outlook. Recognized for its excellence in delivering innovative and high-quality solutions in mRNA manufacturing, EsJ has demonstrated significant advancements in this [...]
Featured News
Research achievement using iPSC-derived neurons published in the American scientific journal, iScience
March 30, 2023
A joint research of Ricoh and the University of Tokyo TOKYO, March 27, 2023 – Ricoh's research group at the Biomedical R&D Department, led by Waka Lin, and Yuko Sekino, Project Professor at the Graduate School of Agriculture and Life Sciences, the University of Tokyo, have jointly demonstrated that transcription factor-induced human iPSC-derived neurons reach functional [...]
All News
Filter By Year
TriLink BioTechnologies® Signs Non-exclusive License and Supply Agreement with Elixirgen Scientific Japan for CleanCap® mRNA capping technology
September 26, 2023
TriLink CleanCap® mRNA capping technology now accessible to ESJ customers for non-commercial use FUJISAWA (SEPTEMBER 26, 2023) – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has entered into a non-exclusive License and Supply Agreement for TriLink’s CleanCap® mRNA capping technology with Elixirgen Scientific Japan, Inc […]
Ricoh to strengthen support for drug discovery services using mRNA. Agreement reached with Elixirgen Scientific, a biotechnology company, to acquire additional shares
May 17, 2022
TOKYO, May 17, 2022 – Ricoh Company, Ltd. and Elixirgen Scientific, Inc. (Baltimore, Maryland, USA) announce that they have agreed and signed a contract for Ricoh to acquire a majority stake in Elixirgen Scientific. Ricoh had previously acquired 34.5% of Elixirgen Scientific’s stock in 2019. By having Elixirgen Scientific as its subsidiary, Ricoh aims to […]
